mirtazapine has been researched along with Chemical Dependence in 9 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Mirtazapine (Remeron®) is a unique FDA-approved antidepressant, with negligible affinity for reuptake proteins, indirectly augments monoamine transmission presumably through antagonist activity at multiple receptors including the norepinephrine (NE)(α2), and serotonin (5-HT)(2A/C) receptors." | 2.48 | Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. ( Graves, SM; Napier, TC; Rafeyan, R; Watts, J, 2012) |
| "Mirtazapine is a comparatively new antidepressant that selectively blocks central alpha2-adrenergic autoreceptors and postsynaptic 5-HT2 and 5-HT3 receptors, causing reduced neuronal norepinephrine and serotonin reuptake." | 1.34 | Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. ( Bateman, DN; Good, AM; Waring, WS, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Naji, L | 1 |
| Dennis, B | 1 |
| Rosic, T | 1 |
| Wiercioch, W | 1 |
| Paul, J | 1 |
| Worster, A | 1 |
| Thabane, L | 1 |
| Samaan, Z | 1 |
| Ma, L | 1 |
| Cunningham, KA | 1 |
| Anastasio, NC | 1 |
| Bjork, JM | 1 |
| Taylor, BA | 1 |
| Arias, AJ | 1 |
| Riley, BP | 1 |
| Snyder, AD | 1 |
| Moeller, FG | 1 |
| Rosenqvist, TW | 1 |
| Osler, M | 1 |
| Wium-Andersen, MK | 1 |
| Wium-Andersen, IK | 1 |
| Lauhan, R | 1 |
| Hsu, A | 1 |
| Alam, A | 1 |
| Beizai, K | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 2 |
| Luther, JF | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 2 |
| Holt, C | 1 |
| Butler, S | 1 |
| Agius, M | 1 |
| Zaman, R | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Gaynes, BN | 1 |
| Howland, RH | 1 |
| Zisook, S | 1 |
| Balasubramani, GK | 1 |
| Fava, M | 1 |
| Graves, SM | 1 |
| Rafeyan, R | 1 |
| Watts, J | 1 |
| Napier, TC | 1 |
| Waring, WS | 1 |
| Good, AM | 1 |
| Bateman, DN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Clinical Studies on Anti-addictive Therapeutic Effects of Mirtazapine in Human Subjects Addicted to Cocaine.[NCT01949571] | Phase 2 | 64 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mirtazapine and Chemical Dependence
| Article | Year |
|---|---|
Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis.
Topics: Central Nervous System Stimulants; Female; Humans; Male; Methamphetamine; Mirtazapine; Remission Ind | 2022 |
Tianeptine Abuse and Dependence: Case Report and Literature Review.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Diazepam; Female; Gabapentin; Hu | 2018 |
Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.
Topics: Animals; Antidepressive Agents, Tricyclic; Central Nervous System Stimulants; Conditioning, Psycholo | 2012 |
2 trials available for mirtazapine and Chemical Dependence
| Article | Year |
|---|---|
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
4 other studies available for mirtazapine and Chemical Dependence
| Article | Year |
|---|---|
A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.
Topics: Cocaine; Cocaine-Related Disorders; Gyrus Cinguli; Humans; Mirtazapine; Serotonin; Substance-Related | 2022 |
Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study.
Topics: Benzodiazepines; Denmark; Drug Prescriptions; Drug Utilization; Female; Humans; Hypnotics and Sedati | 2023 |
An audit to compare patient factors (age, sex, social background & associated physical diagnoses) in people with refractory depression in a Bedfordshire Community Mental Health Team (BCMHT) being augmented with (A) mirtazepine, (B) atypical antipsychotics
Topics: Adult; Age Distribution; Alcoholism; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combine | 2011 |
Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Drug Overdose; Female; | 2007 |